The bispecific antibody Ivanesimab binds to the VEGF dimer, creating a "daisy chain" of antibody-VEGF complexes. This multimerization concentrates the drug in the tumor microenvironment, where VEGF is high, and enhances its ability to bind and block PD-1 more effectively than single-molecule approaches.

Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.

While Akiso's Harmony 6 trial in China showed a survival benefit for its PD-1/VEGF bispecific with chemotherapy, it doesn't resolve the key question of whether these impressive results from Chinese populations will translate to a global patient population.

Data from J&J's Majestic 3 trial suggests its off-the-shelf bispecific combination could rival the efficacy of its own blockbuster CAR-T, Carvykti. This sets up an internal competition where a more accessible therapy could challenge a complex, personalized one in earlier lines of treatment.

The traditional drug-centric trial model is failing. The next evolution is trials designed to validate the *decision-making process* itself, using platforms to assign the best therapy to heterogeneous patient groups, rather than testing one drug on a narrow population.

Market access isn't a launch activity; it's a pre-launch strategy. Its most crucial input is during early clinical trial design, ensuring the right comparators and endpoints are chosen to satisfy payers years down the line. Post-hoc fixes are impossible.

As anyone can easily obtain an antibody for a target, the value of a single patent on a construct decreases. The real premium and competitive advantage will come from late-stage clinical development, clever indication selection, and superior trial execution.

Ocular Therapeutix's trial prioritized a primary endpoint designed to satisfy FDA requirements for a superiority label—a key regulatory win. However, the CEO stresses that clinicians use different metrics like OCT fluid, where their drug "easily beat Eylea." This highlights a crucial strategy: separate the endpoint needed for approval from the data that drives physician adoption.

Unlike bevacizumab's long 20-day half-life and associated bleeding risks that excluded squamous cell carcinoma patients, new bispecifics have a ~6-day half-life. This results in a similar but less severe toxicity profile, broadening their clinical application to a wider patient population.